Clinical Trials Logo

Non-Hodgkin's Lymphoma (NHL) clinical trials

View clinical trials related to Non-Hodgkin's Lymphoma (NHL).

Filter by:

NCT ID: NCT00889798 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Tumor Registry of Lymphatic Neoplasia

TLN-Registry
Start date: April 2009
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

NCT ID: NCT00614042 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and non-Hodgkin's lymphoma.

NCT ID: NCT00511082 Unknown status - Clinical trials for Multiple Myeloma(MM)

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Start date: December 2007
Phase: Phase 1
Study type: Interventional

- To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple Myeloma(MM) - To determine the potential dose-limiting toxicities and maximum-tolerated dose in patients treated with OPB-31121 - To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients

NCT ID: NCT00185679 Terminated - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Haploid Allogeneic Transplant Using the CliniMACS System

Start date: November 2001
Phase: Phase 2
Study type: Interventional

To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.

NCT ID: NCT00129090 Completed - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma

Start date: March 2003
Phase: Phase 3
Study type: Interventional

According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2 or 3) results in a better time to treatment failure (TTTF)

NCT ID: NCT00089284 Terminated - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Start date: October 28, 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug. This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma.